Flucloxacillin bone and soft tissue concentrations assessed by microdialysis in pigs after intravenous and oral administration.
Animal model
Bone
Flucloxacillin
Infection
Osteomyelitis
Journal
Bone & joint research
ISSN: 2046-3758
Titre abrégé: Bone Joint Res
Pays: England
ID NLM: 101586057
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
16
1
2021
Statut:
ppublish
Résumé
Flucloxacillin is commonly administered intravenously for perioperative antimicrobial prophylaxis, while oral administration is typical for prophylaxis following smaller traumatic wounds. We assessed the time, for which the free flucloxacillin concentration was maintained above the minimum inhibitory concentration ( A total of 16 pigs were randomly allocated to either intravenous (Group IV) or oral (Group PO) flucloxacillin 1 g every six hours during a 24-hour period. Microdialysis was used for sampling in cancellous and cortical bone, subcutaneous tissue, and the knee joint. In addition, plasma was sampled. The flucloxacillin Intravenous administration resulted in longer Although intravenous administration of flucloxacillin 1 g provided higher fT > MIC for the low MIC target compared to oral administration, concentrations were surprisingly low, particularly for bone tissue. Achievement of sufficient bone and soft tissue flucloxacillin concentrations may require a dose increase or continuous administration. Cite this article:
Identifiants
pubmed: 33448872
doi: 10.1302/2046-3758.101.BJR-2020-0250.R1
pmc: PMC7845458
doi:
Types de publication
Journal Article
Langues
eng
Pagination
60-67Références
Eur J Vasc Endovasc Surg. 2009 Jun;37(6):696-703
pubmed: 19328028
J Antimicrob Chemother. 2016 Jul;71(7):2037-46
pubmed: 27090629
Antimicrob Agents Chemother. 2007 Sep;51(9):3290-7
pubmed: 17576847
Acta Orthop. 2018 Feb;89(1):95-100
pubmed: 28914105
Scand J Infect Dis Suppl. 1978;(14):135-42
pubmed: 100872
AJR Am J Roentgenol. 2004 Feb;182(2):353-60
pubmed: 14736661
J Bone Jt Infect. 2020 Jan 1;5(1):16-24
pubmed: 32117685
Ulster Med J. 2019 May;88(2):111-114
pubmed: 31061560
Antimicrob Agents Chemother. 2015 Jan;59(1):67-75
pubmed: 25313214
Int J Antimicrob Agents. 2015 Oct;46(4):434-8
pubmed: 26260192
Mol Neurobiol. 2017 Jul;54(5):3506-3527
pubmed: 27189617
Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3280
pubmed: 32176444
Spine J. 2016 Mar;16(3):432-8
pubmed: 26620946
Bone Joint Res. 2019 Aug 2;8(7):313-322
pubmed: 31463039
Antimicrob Agents Chemother. 2014 Jun;58(6):3200-5
pubmed: 24663019
APMIS. 2019 Dec;127(12):779-788
pubmed: 31515843
Clin Pharmacokinet. 2009;48(2):89-124
pubmed: 19271782
Int Orthop. 2011 Jan;35(1):37-42
pubmed: 20213514
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29530848
PLoS Med. 2015 May 19;12(5):e1001825
pubmed: 25992781
J Antimicrob Chemother. 2010 Aug;65(8):1771-8
pubmed: 20530507
Pharm Res. 2007 May;24(5):1014-25
pubmed: 17458685
Int Orthop. 1982;6(4):243-7
pubmed: 7183576
Biopharm Drug Dispos. 1994 Oct;15(7):599-608
pubmed: 7849235
J Clin Pathol. 1978 Aug;31(8):705-11
pubmed: 690233
Int J Infect Dis. 2020 Mar;92:133-140
pubmed: 31978581
Scand J Infect Dis Suppl. 1990;74:63-70
pubmed: 2097720
Acta Orthop. 2018 Dec;89(6):683-688
pubmed: 30080983
Proteomics Clin Appl. 2009 Jun;3(6):720-9
pubmed: 21136982
N Engl J Med. 2019 Jan 31;380(5):425-436
pubmed: 30699315
Clin Pharmacokinet. 2011 Feb;50(2):99-110
pubmed: 21142293
Bone Joint J. 2017 Mar;99-B(3):358-364
pubmed: 28249976
PLoS One. 2018 Jul 12;13(7):e0199370
pubmed: 30001392
J Knee Surg. 2019 Dec 30;:
pubmed: 31887761
Am J Infect Control. 1999 Apr;27(2):97-132; quiz 133-4; discussion 96
pubmed: 10196487
Bone Joint J. 2020 Jun;102-B(6_Supple_A):3-9
pubmed: 32475278
Antimicrob Agents Chemother. 1986 Nov;30(5):729-32
pubmed: 3800349
Int J Med Microbiol. 2010 Feb;300(2-3):193-204
pubmed: 19889575
Br J Clin Pharmacol. 2018 Oct;84(10):2311-2316
pubmed: 29908071